eligibility_summary
Eligible: 18–75 yrs, ECOG ≤2, life expectancy >3 mo, advanced/metastatic solid tumors after ≥1 line or no standard 1st line, CD70 ≥30%, measurable disease, tumor tissue ≤6 mo (rebiopsy willing), adequate organs, contraception/negative pregnancy test, consent. Exclude: recent steroids/immuno/chemo, pregnancy, HIV/active HBV/HCV, allergy, prior organ/allo‑HSCT, recent major surgery, active brain mets, other recent cancers, serious illness, recent vaccine, prior CD70 CAR‑T, other trials, PI judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II single-arm study of autologous CD70-targeted CAR-T cells in CD70+ advanced/metastatic solid tumors. Intervention: CD70-CAR-T (genetically engineered autologous T-cell therapy) given after preconditioning with albumin-bound paclitaxel (taxane microtubule stabilizer chemotherapy), cyclophosphamide (alkylating agent), and fludarabine (purine analog antimetabolite). Mechanism: CAR-T recognizes CD70 on tumor cells, triggering T-cell activation, cytolysis, and cytokine release, preconditioning lymphodepletes and may debulk tumor to enhance CAR-T expansion. Targets: CD70-expressing tumor cells/CD70-CD27 axis, host lymphocytes (cyclophosphamide, fludarabine) and microtubules in dividing cells (nab-paclitaxel).